About EryDel
EryDel is a company based in Milan (Italy) founded in 2007 by Giovanni Mambrini was acquired by Quince Therapeutics in July 2023.. EryDel has raised $31.7 million across 3 funding rounds from investors including Quince Therapeutics, European Union and Genextra. EryDel offers products and services including eDSP and AIDE Platform. EryDel operates in a competitive market with competitors including Sirnaomics, Arcturus Therapeutics, ViAqua, PharmaJet and Vaxxas, among others.
- Headquarter Milan, Italy
- Founders Giovanni Mambrini
-
Sectors
TechnologyHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Quince Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31.7 M (USD)
in 3 rounds
-
Latest Funding Round
$31.7 M (USD), Series B
Apr 24, 2018
-
Investors
Quince Therapeutics
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Quince Therapeutics
(Jul 24, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EryDel
EryDel offers a comprehensive portfolio of products and services, including eDSP and AIDE Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Encapsulated dexamethasone for treating Ataxia-Telangiectasia in patients.
Technology platform for encapsulating drugs into red blood cells.
Funding Insights of EryDel
EryDel has successfully raised a total of $31.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31.7 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $31.7M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2018 | Amount | Series B - EryDel | Valuation | Sofinnova Partners | |
| Jan, 2016 | Amount | Grant - EryDel | Valuation |
investors |
|
| Jul, 2013 | Amount | Series B - EryDel | Valuation | Genextra |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EryDel
EryDel has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Quince Therapeutics, European Union and Genextra. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A holding company focused on life science investments is operated.
|
Founded Year | Domain | Location | |
|
VC firm investing in seed and early stage companies in Italy
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EryDel
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EryDel
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Erydel Comparisons
Competitors of EryDel
EryDel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Arcturus Therapeutics, ViAqua, PharmaJet and Vaxxas, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| domain | founded_year | HQ Location |
RNAi drug delivery technology is developed for aquaculture disease prevention.
|
|
| domain | founded_year | HQ Location |
Provider of needle-free injection technology
|
|
| domain | founded_year | HQ Location |
Developer of vaccines to treat cancer and infectious diseases
|
|
| domain | founded_year | HQ Location |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Erydel
Frequently Asked Questions about EryDel
When was EryDel founded?
EryDel was founded in 2007 and raised its 1st funding round 6 years after it was founded.
Where is EryDel located?
EryDel is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Is EryDel a funded company?
EryDel is a funded company, having raised a total of $31.7M across 3 funding rounds to date.
What does EryDel do?
EryDel was founded in 2007 in Milan, Italy, focusing on biotechnology and drug delivery innovations. Operations center on the proprietary red cell loader (RCL) device and erykit, which enable loading of small molecules, proteins, and enzymes into human red blood cells. Therapeutics in the pipeline include erdex, advanced to phase 3 clinical trials, and eetm, completed through phase 2.
Who are the top competitors of EryDel?
EryDel's top competitors include Sirnaomics, Arcturus Therapeutics and PharmaJet.
What products or services does EryDel offer?
EryDel offers eDSP and AIDE Platform.
Who are EryDel's investors?
EryDel has 6 investors. Key investors include Quince Therapeutics, European Union, Genextra, Innogest Capital, and Focus Gestioni SGR.